2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists

Author(s): Sirimas Sudsakorn, Praveen Bahadduri, Jennifer Fretland, Chuang Lu*

Journal Name: Current Drug Metabolism

Volume 21 , Issue 6 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: In January 2020, the US FDA published two final guidelines, one entitled “In vitro Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry” and the other entitled “Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry”. These were updated from the 2017 draft in vitro and clinical DDI guidance.

Methods: This study is aimed to provide an analysis of the updates along with a comparison of the DDI guidelines published by the European Medicines Agency (EMA) and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) along with the current literature.

Results: The updates were provided in the final FDA DDI guidelines and explained the rationale of those changes based on the understanding from research and literature. Furthermore, a comparison among the FDA, EMA, and PMDA DDI guidelines are presented in Tables 1, 2 and 3.

Conclusion: The new 2020 clinical DDI guidance from the FDA now has even higher harmonization with the guidance (or guidelines) from the EMA and PMDA. A comparison of DDI guidance from the FDA 2017, 2020, EMA, and PMDA on CYP and transporter based DDI, mathematical models, PBPK, and clinical evaluation of DDI is presented in this review.

Keywords: Cytochrome P450, CYP, transporter, DDI, PK interaction, clinical DDI risk, PBPK, in vitro assay.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 6
Year: 2020
Page: [403 - 426]
Pages: 24
DOI: 10.2174/1389200221666200620210522
Price: $65

Article Metrics

PDF: 56